Acuta Capital Partners’s Merck MRK Stock Holding History

Acuta Capital Partners’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-22,994	Closed	-$2.06M	–	34
2025 Q1	$2.06M	Buy	+22,994	New	+$2.15M	2.39%	17

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Acuta Capital Partners's MRK Position: Q2 2025 in Review

Acuta Capital Partners sold out of Merck (MRK) in Q2 2025, closing a stake of 22,994 shares — an estimated $2.06M sold.

Acuta Capital Partners first reported a position in MRK in Q1 2025 and held it in 1 quarter. The position peaked at $2.06M in Q1 2025. 3,328 funds tracked by Wall St. Rank hold MRK as of Q2 2025.

Acuta Capital Partners reported no remaining Merck position as of Q2 2025 after selling out during the quarter.
Acuta Capital Partners sold 22,994 Merck shares in Q2 2025, an estimated $2.06M.
Acuta Capital Partners first reported a position in Merck in Q1 2025 and held it in 1 quarter.
Acuta Capital Partners's Merck position peaked at $2.06M in Q1 2025.
3,328 funds tracked by Wall St. Rank held Merck as of Q2 2025.

Based on Acuta Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.